This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cappelletty, D. M. Articles by Rybak, M. J. Search for Related Content PubMed PubMed Citation Articles by Cappelletty, D. M. Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Aug 1995, 1797-1801, Vol 39, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

DM Cappelletty, SL Kang, SM Palmer and MJ Rybak
Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, Michigan, USA.

We compared the pharmacodynamics and killing activity of ceftazidime, administered by continuous infusion and intermittent bolus, against Pseudomonas aeruginosa ATCC 27853 and ceftazidime-resistant P. aeruginosa 27853CR with and without a single daily dose of amikacin in an in vitro infection model over a 48-h period. Resistance to ceftazidime was selected for by serial passage of P. aeruginosa onto agar containing increasing concentrations of ceftazidime. Human pharmacokinetics and dosages were simulated as follows: half-life, 2 h; intermittent-bolus ceftazidime, 2 g every 8 h (q8h) and q12h; continuous infusion, 2-g loading dose and maintenance infusions of 5, 10, and 20 micrograms/ml; amikacin, 15 mg/kg q24h. There was no significant difference in time to 99.9% killing between any of the monotherapy regimens or between any combination regimen against ceftazidime-susceptible P. aeruginosa. Continuous infusions of 10 and 20 micrograms/ml killed as effectively as an intermittent bolus of 2 g q12h and q8h, respectively. Continuous infusion of 20 micrograms/ml and an intermittent bolus of 2 g q8h were the only regimens which prevented organism regrowth at 48 h, while a continuous infusion of 5 micrograms/ml resulted in the most regrowth. All of the combination regimens exhibited a synergistic response, with rapid killing of ceftazidime-susceptible P. aeruginosa and no regrowth. Against ceftazidime-resistant P. aeruginosa, none of the ceftazidime monotherapy regimens achieved 99.9% killing. The combination regimens exhibited the same rapid killing of the resistant strain as occurred with the susceptible strain; however, regrowth occurred with all regimens.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

• Moriyama, B., Henning, S. A, Neuhauser, M. M, Danner, R. L, Walsh, T. J (2009). Continuous-Infusion {beta}-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria. The Annals of Pharmacotherapy 43: 1324-1337 [Abstract] [Full Text]  
• Bulitta, J. B., Ly, N. S., Yang, J. C., Forrest, A., Jusko, W. J., Tsuji, B. T. (2009). Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 46-56 [Abstract] [Full Text]  
• Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.-F., Potel, G., Bugnon, D. (2002). In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 46: 3706-3711 [Abstract] [Full Text]  
• Mayer, I., Nagy, E. (1999). Investigation of the synergic effects of aminoglycoside- fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.. J Antimicrob Chemother 43: 651-657 [Abstract] [Full Text]  
• Cappelletty, D. M. (1999). Evaluation of Several Dosing Regimens of Cefepime, with Various Simulations of Renal Function, against Clinical Isolates of Pseudomonas aeruginosa in a Pharmacodynamic Infection Model. Antimicrob. Agents Chemother. 43: 129-133 [Abstract] [Full Text]